WoundReference improves clinical decisions
 Choose the role that best describes you
Hubbard VG, Friedmann AC, Goldsmith P, et al.
The British journal of dermatology. Date of publication 2005 May 1;volume 152(5):1059-61.
1. Br J Dermatol. 2005 May;152(5):1059-61. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Hubbard VG(1), Friedmann AC, Goldsmith P. Author information: (1)Department of Dermatology, Royal London Hospital, Whitechapel Road, London E1 1BB, UK. vghubbard@yahoo.co.uk Pyoderma gangrenosum (PG) is frequently associated with constitutional symptoms as part of a nonspecific inflammatory response. However, extracutaneous discrete aseptic neutrophilic infiltrates are extremely rare. We report a patient with idiopathic PG with splenic and psoas muscle involvement. His disease was extremely aggressive and was unresponsive to conventional immunosuppressive therapy. His cutaneous and extracutaneous PG cleared with infliximab and adalimumab. DOI: 10.1111/j.1365-2133.2005.06467.x PMID: 15888172 [Indexed for MEDLINE]
Appears in following Topics:
Pyoderma Gangrenosum - Treatment